[Inhibitors of factor XIIIa].
Factor XIIIa (FXIIIa) catalyzes the covalent crosslinking of fibrin polymers and incorporation of proteins into the fibrin network and thus confers on the thrombus additional structural stability and relative resistance to plasmin-mediated degradation. Moreover, FXIIIa is involved in other physiological and pathophysiological processes such as wound healing and arteriosclerosis. Selective FXIIIa inhibitors may be a valuable tool for evaluation of the various functions of FXIIIa and their pharmacological control. This paper presents an overview of the inhibitors of FXIIIa. Analogues of natural FXIIIa substrates - including glutamine containing peptides and low molecular weight substituted alkylamines - are incorporated into the fibrin network and thus prevent crosslinking of fibrin. Naturally occurring, direct inhibitors of FXIIIa have been isolated from a leech species and microorganisms. With effective concentrations in the nanomolar range the peptide tridegin is the most potent FXIIIa inhibitor up to now. The majority of the synthetic, low molecular Weight inhibitors bind covalently to Cys314 at the active site of FXIIIa. Besides the relatively nonspecific thiol reagents, azol derivatives, azolium salts and related substances are described as specific inhibitors of FXIIIa. They inhibit the activity of FXIIIa at nanomolar concentrations. Animal experiments have demonstrated improved thrombolysis by a plasminogen activator in combination with a FXIIIa inhibitor.
Klinikum der Friedrich-Schiller-Universität Jena, Zentrum für Vaskuläre Biologie und Medizin, Erfurt. prasa@zmkh.ef.uni-jena.de
D
D
Prasa
J
J
Stürzebecher
D001161:Arteriosclerosis / Q000097:blood; D026122:Factor XIIIa / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D006801:Humans; D012471:Salivary Proteins and Peptides / Q000494:pharmacology; D014945:Wound Healing / Q000502:physiology*
D012471:Salivary Proteins and Peptides; C106835:tridegin; D026122:Factor XIIIa